Mitochondrial DNA Depletion clinical trials at UCSD

1 research study open to eligible people

Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
open to eligible people ages 18-70
SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary mitochondrial myopathy associated with nuclear DNA mutations (nPMD).
San Diego, California and other locations

Last updated: July 17, 2023

Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)